Silence Therapeutics said this week that it has begun a consolidation effort to streamline its operations following its acquisition of Intradigm (RNAi News 12/17/2009).
According to Silence, all research activities of the merged company will be conducted at its Berlin location. Silence, which is based in London, has maintained German operations since its 2005 acquisition of Atugen (RNAi News 7/29/2005).
Other functions including operations, business development, legal, and "certain drug-development activities, will be conducted in Palo Alto," Calif., where Intradigm was headquartered.
Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development, at both the Palo Alto and Berlin sites. The reorganization is expected to be completed in June.